# eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam

> **NCT01484977** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 120 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Lacosamide

## Key facts

- **NCT ID:** NCT01484977
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2018-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01484977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01484977, "eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01484977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*